LNCR3
MCID: LNG064
MIFTS: 79

Lung Cancer Susceptibility 3 (LNCR3)

Categories: Cancer diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer Susceptibility 3

MalaCards integrated aliases for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 58 13 74
Lung Adenocarcinoma 39 12 54 30 6 15 17
Adenocarcinoma of Lung 58 12 77 74
Adenocarcinoma of Lung, Susceptibility to 58
Bronchogenic Lung Adenocarcinoma 12
Non-Small Cell Adenocarcinoma 74
Nonsmall Cell Adenocarcinoma 12
Adenocarcinoma Lung 56
Lncr3 58

Classifications:



External Ids:

Disease Ontology 12 DOID:3910
OMIM 58 612571
MeSH 45 C538231
NCIt 51 C27745 C3512

Summaries for Lung Cancer Susceptibility 3

NIH Rare Diseases : 54 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. The underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and HIV infection. Treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. It may include a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and/or watchful waiting.

MalaCards based summary : Lung Cancer Susceptibility 3, also known as lung adenocarcinoma, is related to mucinous lung adenocarcinoma and lung cancer. An important gene associated with Lung Cancer Susceptibility 3 is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs leucovorin and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A lung cancer that derives from epithelial cells of glandular origin.

Wikipedia : 77 Adenocarcinoma of the lung (also known as pulmonary adenocarcinoma) is the most common type of lung... more...

Description from OMIM: 612571

Related Diseases for Lung Cancer Susceptibility 3

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 1 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 5

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 467)
# Related Disease Score Top Affiliating Genes
1 mucinous lung adenocarcinoma 35.1 ALK EGFR ERBB2 HRAS KRAS ROS1
2 lung cancer 34.4 AKT1 ALK BRAF CDK4 EGFR ERBB2
3 lung squamous cell carcinoma 33.7 AKT1 ALK BRAF EGFR FGFR3 HRAS
4 lung papillary adenocarcinoma 33.6 ALK NFE2L2 TP53
5 adenocarcinoma 32.5 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
6 breast cancer 31.8 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
7 thyroid cancer 31.7 AKT1 BRAF CTNNB1 EGFR HRAS KRAS
8 colorectal cancer 31.7 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
9 small cell cancer of the lung 31.6 AKT1 EGFR PIK3CA TP53
10 sarcoma 31.6 BRAF CDK4 CTNNB1 HRAS KRAS PIK3CA
11 hepatocellular carcinoma 31.5 AKT1 CDK4 CTNNB1 EGFR HRAS KRAS
12 ovarian cancer 31.4 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
13 prostate cancer 31.4 AKT1 CDK4 CTNNB1 EGFR ERBB2 HRAS
14 melanoma 31.3 BRAF CDK4 MAP2K1 NRAS TP53
15 cervical cancer 31.3 AKT1 CTNNB1 ERBB2 FGFR3 HRAS NFE2L2
16 gastric cancer 31.2 AKT1 CTNNB1 EGFR ERBB2 KRAS PIK3CA
17 pancreatic cancer 31.2 AKT1 CDK4 CTNNB1 EGFR ERBB2 HRAS
18 gastric adenocarcinoma 31.2 AKT1 BRAF CTNNB1 EGFR ERBB2 HRAS
19 adenoid cystic carcinoma 31.1 AKT1 CTNNB1 ERBB2 HRAS KRAS PIK3CA
20 squamous cell carcinoma 31.1 AKT1 BRAF CTNNB1 EGFR ERBB2 FGFR3
21 cholangiocarcinoma 31.1 AKT1 BRAF CTNNB1 EGFR ERBB2 KRAS
22 glioblastoma 31.1 AKT1 ALK BRAF CDK4 EGFR ERBB2
23 glioma 31.1 BRAF CDK4 EGFR ERBB2 PIK3CA TP53
24 pancreas adenocarcinoma 31.0 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
25 esophageal cancer 31.0 AKT1 CDK4 CTNNB1 EGFR ERBB2 HRAS
26 differentiated thyroid carcinoma 30.9 ALK BRAF EGFR HRAS KRAS NRAS
27 suppression of tumorigenicity 12 30.9 AKT1 BRAF CTNNB1 HRAS PIK3CA SMAD4
28 ovarian serous cystadenocarcinoma 30.9 AKT1 BRAF ERBB2 HRAS NRAS PIK3CA
29 breast adenocarcinoma 30.9 AKT1 EGFR ERBB2 KRAS PIK3CA SMAD4
30 bladder cancer 30.9 CDK4 EGFR ERBB2 FGFR3 HRAS KRAS
31 colorectal adenocarcinoma 30.9 BRAF CTNNB1 EGFR HRAS KRAS TP53
32 endometrial adenocarcinoma 30.9 AKT1 CTNNB1 EGFR ERBB2 KRAS TP53
33 ovarian cancer 1 30.8 AKT1 ERBB2 KRAS PIK3CA TP53
34 gastrointestinal stromal tumor 30.8 AKT1 BRAF EGFR KRAS TP53
35 adrenocortical carcinoma, hereditary 30.8 BRAF CTNNB1 NRAS PIK3CA TP53
36 lynch syndrome 30.8 BRAF CTNNB1 EGFR KRAS TP53
37 melanoma, uveal 30.8 BRAF CDK4 NRAS
38 large cell carcinoma 30.8 EGFR ROS1 STK11
39 adenoma 30.8 BRAF CTNNB1 KRAS SMAD4 TP53
40 intrahepatic cholangiocarcinoma 30.7 CTNNB1 EGFR KRAS TP53
41 lymphoma, non-hodgkin, familial 30.7 ALK BRAF NRAS PIK3CA TP53
42 familial adenomatous polyposis 30.7 CTNNB1 KRAS SMAD4 TP53
43 thymoma 30.6 AKT1 EGFR HRAS TP53
44 mucinous adenocarcinoma 30.5 ALK EGFR KRAS
45 signet ring lung adenocarcinoma 12.3
46 bronchiolo-alveolar adenocarcinoma 11.9
47 tumor predisposition syndrome 11.5
48 lung occult adenocarcinoma 11.1
49 lung cancer susceptibility 1 11.1
50 large intestine cancer 11.1 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

Clinical features from OMIM:

612571

GenomeRNAi Phenotypes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

27 (show top 50) (show all 80)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.33 BRAF EGFR PIK3CA HRAS KRAS
2 Decreased viability GR00106-A-0 11.33 KRAS
3 Decreased viability GR00107-A-1 11.33 MAP2K1
4 Decreased viability GR00221-A-1 11.33 AKT1 ALK EGFR PIK3CA FGFR3 HRAS
5 Decreased viability GR00221-A-2 11.33 AKT1 PIK3CA FGFR3 HRAS KRAS RAF1
6 Decreased viability GR00221-A-3 11.33 AKT1 ERBB2 FGFR3 HRAS MAP2K1 NRAS
7 Decreased viability GR00221-A-4 11.33 AKT1 ALK BRAF EGFR ERBB2 PIK3CA
8 Decreased viability GR00231-A 11.33 RAF1
9 Decreased viability GR00301-A 11.33 BRAF KRAS RAF1
10 Decreased viability GR00342-S-1 11.33 MAP2K1 ROS1
11 Decreased viability GR00342-S-2 11.33 MAP2K1
12 Decreased viability GR00342-S-3 11.33 MAP2K1
13 Decreased viability GR00381-A-1 11.33 BRAF KRAS
14 Decreased viability GR00402-S-2 11.33 AKT1 ALK BRAF EGFR ERBB2 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.94 PRKN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.94 CTNNB1 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.94 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.94 CTNNB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.94 FGFR3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.94 CDK4
21 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.94 PIK3CA CDK4
22 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.94 EGFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.94 KRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.94 EGFR FGFR3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.94 BRAF
26 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.94 PIK3CA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.94 AKT1 PIK3CA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.94 ERBB2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.94 ERBB2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.94 BRAF PIK3CA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.94 KRAS ERBB2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.94 PRKN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.94 AKT1 BRAF CTNNB1 KRAS PIK3CA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.94 PIK3CA EGFR
35 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.94 BRAF
36 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.94 KRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.94 CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.94 PRKN
39 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.94 PRKN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.94 ERBB2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.94 CDK4 EGFR
42 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.94 EGFR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.94 KRAS
44 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.94 BRAF
45 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.94 BRAF
46 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.94 BRAF ERBB2
47 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.94 PRKN
48 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.94 AKT1 PIK3CA CDK4
49 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.94 EGFR
50 Increased shRNA abundance (Z-score > 2) GR00366-A-45 10.94 PRKN

MGI Mouse Phenotypes related to Lung Cancer Susceptibility 3:

47 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.58 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
2 growth/size/body region MP:0005378 10.57 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
3 behavior/neurological MP:0005386 10.56 AKT1 ALK BRAF CDK4 CTNNB1 ERBB2
4 cardiovascular system MP:0005385 10.56 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
5 homeostasis/metabolism MP:0005376 10.54 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
6 integument MP:0010771 10.53 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
7 endocrine/exocrine gland MP:0005379 10.5 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
8 mortality/aging MP:0010768 10.49 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
9 embryo MP:0005380 10.48 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
10 craniofacial MP:0005382 10.46 BRAF CTNNB1 EGFR ERBB2 FGFR3 HRAS
11 digestive/alimentary MP:0005381 10.46 BRAF CDK4 CTNNB1 EGFR ERBB2 FGFR3
12 neoplasm MP:0002006 10.43 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
13 nervous system MP:0003631 10.41 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
14 immune system MP:0005387 10.4 AKT1 BRAF CDK4 CTNNB1 EGFR FGFR3
15 hematopoietic system MP:0005397 10.39 AKT1 BRAF CDK4 CTNNB1 EGFR FGFR3
16 normal MP:0002873 10.33 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
17 muscle MP:0005369 10.31 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
18 liver/biliary system MP:0005370 10.3 AKT1 BRAF CDK4 CTNNB1 EGFR KRAS
19 no phenotypic analysis MP:0003012 10.21 CTNNB1 EGFR FGFR3 HRAS KRAS NRAS
20 hearing/vestibular/ear MP:0005377 10.19 BRAF CTNNB1 EGFR FGFR3 KRAS MAP2K1
21 limbs/digits/tail MP:0005371 10.19 BRAF CTNNB1 EGFR ERBB2 FGFR3 KRAS
22 reproductive system MP:0005389 10.13 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
23 renal/urinary system MP:0005367 10.06 BRAF CDK4 CTNNB1 EGFR FGFR3 HRAS
24 respiratory system MP:0005388 10 AKT1 ALK BRAF CTNNB1 EGFR ERBB2
25 pigmentation MP:0001186 9.97 ALK BRAF CDK4 CTNNB1 EGFR KRAS
26 skeleton MP:0005390 9.89 AKT1 ALK BRAF CTNNB1 EGFR ERBB2
27 vision/eye MP:0005391 9.44 ALK BRAF CDK4 CTNNB1 EGFR FGFR3

Drugs & Therapeutics for Lung Cancer Susceptibility 3

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
2
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 60843 446556
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
5
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
6
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
8
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60-18-4 6057
9 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 183319-69-9 176871
12 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Endostatins Phase 4 71581480
17 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
18 Endostar protein Phase 4,Phase 2
19 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
23
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
24
afatinib Approved Phase 3,Phase 2 850140-72-6, 439081-18-2 10184653
25
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 44424639 60780
26
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
27
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
28
Crizotinib Approved Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
29
Mesna Approved, Investigational Phase 3,Phase 2 3375-50-6 598
30
Loperamide Approved Phase 3 53179-11-6 3955
31
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
32
Vinblastine Approved Phase 3 865-21-4 241903 13342
33
Cetuximab Approved Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
34
Ceritinib Approved Phase 3,Phase 2 1032900-25-6
35
Hydroxocobalamin Approved Phase 3,Not Applicable 13422-51-0 15589840 11953898
36
Methylcobalamin Approved, Experimental, Investigational Phase 3,Not Applicable 13422-55-4
37
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
38
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
39
Ipilimumab Approved Phase 3,Phase 2 477202-00-9
40
nivolumab Approved Phase 3,Phase 1,Phase 2 946414-94-4
41
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
42
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
43
Cyanocobalamin Approved, Nutraceutical Phase 3,Not Applicable 68-19-9 44176380
44
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
45
Cobalamin Experimental Phase 3,Not Applicable 13408-78-1 6857388
46 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
48 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
49 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 394)
# Name Status NCT ID Phase Drugs
1 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
2 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
3 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
4 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
5 Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
6 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
7 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
8 Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients Unknown status NCT01719536 Phase 3 Icotinib;Chemotherapy
9 Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Unknown status NCT01066195 Phase 3 iressa;alimta
10 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
11 First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker Completed NCT00455936 Phase 3 Gefitinib
12 Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma Completed NCT02889692 Phase 3 YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib®
13 Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3 Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel
14 BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) Completed NCT01121393 Phase 3 Gemcitabine+Cisplatin;BIBW 2992
15 BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation Completed NCT00949650 Phase 3 Pemetrexed;BIBW 2992;Cisplatin
16 ADAM-Afatinib Diarrhea Assessment and Management Completed NCT01814553 Phase 3 afatinib;loperamide
17 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer Completed NCT01404260 Phase 3 Gefitinib;Gemcitabine +Carboplatin
18 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
19 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
20 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
21 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
22 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
23 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
24 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
25 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
26 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
27 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
28 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
29 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
30 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
31 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
32 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
33 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
34 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
35 Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma Recruiting NCT03380468 Phase 2, Phase 3 cisplatin plus pemetrexed
36 Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma Recruiting NCT02518802 Phase 3 Gefitinib;Pemetrexed
37 Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) Recruiting NCT02893332 Phase 3 TKI (Gefitinib or Tarceva )
38 Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma Recruiting NCT02281708 Phase 3 vinorelbine plus cisplatin
39 Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma Recruiting NCT02125240 Phase 3 Icotinib;Placebo
40 To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma Recruiting NCT03656393 Phase 3 Gefitinib;Vinorelbine;Carboplatin
41 To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
42 Phase III Trial of (LCT) After Nivolumab and Ipilimumab Recruiting NCT03391869 Phase 3
43 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
44 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
45 Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer Active, not recruiting NCT01407822 Phase 2, Phase 3 Erlotinib;Gemcitabine/cisplatin
46 LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting NCT01828112 Phase 3 Ceritinib;pemetrexed;docetaxel
47 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer Active, not recruiting NCT01828099 Phase 3 Ceritinib;Pemetrexed;Cisplatin;Carboplatin
48 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
49 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
50 Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Enrolling by invitation NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Genetic Tests for Lung Cancer Susceptibility 3

Genetic tests related to Lung Cancer Susceptibility 3:

# Genetic test Affiliating Genes
1 Lung Adenocarcinoma 30

Anatomical Context for Lung Cancer Susceptibility 3

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

42
Lung, Brain, Breast, Thyroid, Lymph Node, Testes, Bone

Publications for Lung Cancer Susceptibility 3

Articles related to Lung Cancer Susceptibility 3:

(show top 50) (show all 4605)
# Title Authors Year
1
Amaurosis fugax as the presenting symptom of metastatic lung adenocarcinoma. ( 31109501 )
2019
2
Prognostic significance of CDC25C in lung adenocarcinoma: An analysis of TCGA data. ( 31109596 )
2019
3
A hypercoagulable state leading to venous limb gangrene associated with occult lung adenocarcinoma. ( 31110709 )
2019
4
Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma. ( 31071530 )
2019
5
Genome-wide analysis reveals alcohol dehydrogenase 1C and secreted phosphoprotein 1 for prognostic biomarkers in lung adenocarcinoma. ( 31074035 )
2019
6
Extracting predictors for lung adenocarcinoma based on Granger causality test and stepwise character selection. ( 31074380 )
2019
7
Durable clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in trans-C797S to combination therapy of first- and third-generation EGFR TKIs. ( 31075545 )
2019
8
Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma. ( 31079342 )
2019
9
Prognostic significance of IFITM1 expression and correlation with microvessel density and epithelial-mesenchymal transition signature in lung adenocarcinoma. ( 31079850 )
2019
10
Oncogenic Effect of the Novel Fusion Gene VAPA-Rab31 in Lung Adenocarcinoma. ( 31083279 )
2019
11
Correlated low IGF2BP1 and FOXM1 expression predicts a good prognosis in lung adenocarcinoma. ( 31085008 )
2019
12
Up-regulation of Insulin-like Growth Factor Binding Protein-3 Is Associated with Brain Metastasis in Lung Adenocarcinoma. ( 31085806 )
2019
13
Combined effects of XAF1 and TRAIL on the apoptosis of lung adenocarcinoma cells. ( 31086598 )
2019
14
Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts. ( 31090071 )
2019
15
MS-275 potentiates the effect of YM-155 in lung adenocarcinoma via survivin downregulation induced by miR-138 and miR-195. ( 31090206 )
2019
16
Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab. ( 31092773 )
2019
17
Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis. ( 31093306 )
2019
18
A Case of Lung Adenocarcinoma Originating from an Old Posttraumatic Scar in a Young Patient. ( 31093394 )
2019
19
Combining fluorine-18 fluorodeoxyglucose positron emission tomography and pathological risk factors to predict postoperative recurrence in stage I lung adenocarcinoma. ( 31095528 )
2019
20
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. ( 31095895 )
2019
21
Exploring the survival prognosis of lung adenocarcinoma based on the cancer genome atlas database using artificial neural network. ( 31096483 )
2019
22
PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation. ( 31098955 )
2019
23
Hypofractionated radiotherapy in nine dogs with unresectable solitary lung adenocarcinoma. ( 31099095 )
2019
24
Clinical and Prognostic Significance of the Epithelial-Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Score-Matched Analysis. ( 31103348 )
2019
25
Prognostic and Predictive Value of Three DNA Methylation Signatures in Lung Adenocarcinoma. ( 31105737 )
2019
26
Evaluation of Plasma Extracellular Vesicle MicroRNA Signatures for Lung Adenocarcinoma and Granuloma With Monte-Carlo Feature Selection Method. ( 31105742 )
2019
27
Lung adenocarcinoma metastasis to pancreas after the absence of primary tumour for almost two years. ( 31105963 )
2019
28
Integrated analysis reveals five potential ceRNA biomarkers in human lung adenocarcinoma. ( 31106044 )
2019
29
A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. ( 31106124 )
2019
30
Spread through air spaces is an independent predictor of recurrence in stage III (N2) lung adenocarcinoma. ( 31106332 )
2019
31
Limited Resection is Associated With a Higher Risk of Locoregional Recurrence than Lobectomy in Stage I Lung Adenocarcinoma With Tumor Spread Through Air Spaces. ( 31107717 )
2019
32
Problems in the Reproducibility of Classification of Small Lung Adenocarcinoma: An International Interobserver Study. ( 31107973 )
2019
33
FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. ( 31027687 )
2019
34
Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. ( 31027691 )
2019
35
STAT1-induced upregulation of LINC00467 promotes the proliferation migration of lung adenocarcinoma cells by epigenetically silencing DKK1 to activate Wnt/β-catenin signaling pathway. ( 31027730 )
2019
36
Long non-coding RNA TTN-AS1 promotes the progression of lung adenocarcinoma by regulating PTEN/PI3K/AKT signaling pathway. ( 31027732 )
2019
37
Response of BRAFV600E-Mutant Lung Adenocarcinoma With Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment. ( 31027751 )
2019
38
Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma. ( 31032816 )
2019
39
Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence. ( 31036704 )
2019
40
HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients. ( 31037158 )
2019
41
LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma. ( 31040157 )
2019
42
The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma. ( 31042721 )
2019
43
Clinical significance of epithelial-mesenchymal transition-related molecules in lung adenocarcinoma. ( 31043817 )
2019
44
PITX2 enhances progression of lung adenocarcinoma by transcriptionally regulating WNT3A and activating Wnt/β-catenin signaling pathway. ( 31043858 )
2019
45
Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma. ( 31044389 )
2019
46
Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report. ( 31045832 )
2019
47
The study of killing effect and inducing apoptosis of 630-nm laser on lung adenocarcinoma A549 cells mediated by hematoporphyrin derivatives in vitro. ( 31049741 )
2019
48
A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma. ( 31050375 )
2019
49
Molecular Pathogenesis of Gene Regulation by the miR-150 Duplex: miR-150-3p Regulates TNS4 in Lung Adenocarcinoma. ( 31052206 )
2019
50
The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma. ( 31052317 )
2019

Variations for Lung Cancer Susceptibility 3

ClinVar genetic disease variations for Lung Cancer Susceptibility 3:

6 (show top 50) (show all 798)
# Gene Variation Type Significance SNP ID Assembly Location
1 PRKN NM_013988.2(PARK2): c.(8_8)_(171_171)+180544del deletion Pathogenic GRCh38 Chromosome 6, 162262766: 162727661
2 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
3 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
4 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
5 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
7 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
8 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
9 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
10 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
11 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
12 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
13 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
14 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
15 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
16 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
17 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
18 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
19 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
20 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
21 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
22 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
23 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
24 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
25 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
26 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
27 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
28 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
29 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
30 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
31 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
32 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
33 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
34 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
35 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
36 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
37 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
38 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
39 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
40 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
41 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
42 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
43 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
44 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
45 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
46 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
47 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
48 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
49 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
50 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

7 (show top 50) (show all 580)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13394 1 1 2300000 Gain Lung adenocarcinoma
2 13409 1 1 2300000 Gain Lung adenocarcinoma
3 13970 1 102000000 107000000 Loss Lung adenocarcinoma
4 13986 1 102200000 107200000 Loss Lung adenocarcinoma
5 14528 1 109314358 109386258 Deletion WDR47 Lung adenocarcinoma
6 15384 1 115048600 115061038 Copy number NRAS Lung adenocarcinoma
7 17560 1 143480000 149410000 Amplification ARNT Lung adenocarcinoma
8 18143 1 144218994 144222801 Amplification RBM8A Lung adenocarcinoma
9 18161 1 144227739 144235088 Amplification PEX11B Lung adenocarcinoma
10 18176 1 144287344 144297903 Amplification PIAS3 Lung adenocarcinoma
11 18223 1 144475951 145932379 Amplification GPR89A Lung adenocarcinoma
12 18385 1 145180914 145234067 Amplification CHD1L Lung adenocarcinoma
13 18405 1 145479805 145564639 Amplification BCL9 Lung adenocarcinoma
14 18433 1 145585791 145609258 Amplification ACP6 Lung adenocarcinoma
15 19003 1 148137824 148138969 Amplification BOLA1 Lung adenocarcinoma
16 19039 1 148305965 148384129 Amplification VPS45 Lung adenocarcinoma
17 19152 1 148885329 148936257 Amplification GOLPH3L Lung adenocarcinoma
18 19199 1 149165511 149203837 Amplification SETDB1 Lung adenocarcinoma
19 19207 1 149221122 149234738 Amplification ANXA9 Lung adenocarcinoma
20 19214 1 149247596 149274813 Amplification PRUNE Lung adenocarcinoma
21 19280 1 149399337 149404960 Amplification LYSMD1 Lung adenocarcinoma
22 19287 1 149415557 149429264 Amplification VPS72 Lung adenocarcinoma
23 19299 1 149493820 149506578 Amplification PSMD4 Lung adenocarcinoma
24 19341 1 149638664 149641036 Amplification PSMB4 Lung adenocarcinoma
25 19375 1 149998746 150002664 Amplification MRPL9 Lung adenocarcinoma
26 19378 1 150009206 150029634 Amplification TDRKH Lung adenocarcinoma
27 19432 1 150271605 150276135 Amplification S100A11 Lung adenocarcinoma
28 20047 1 152787674 152797744 Amplification UBE2Q1 Lung adenocarcinoma
29 20052 1 152821157 152867061 Amplification ADAR Lung adenocarcinoma
30 20569 1 153196125 153200882 Amplification PYGO2 Lung adenocarcinoma
31 20571 1 153201397 153213464 Amplification SHC1 Lung adenocarcinoma
32 20591 1 153213790 153218346 Amplification CKS1B Lung adenocarcinoma
33 20592 1 153222440 153232211 Amplification FLAD1 Lung adenocarcinoma
34 20617 1 153302836 153308653 Amplification EFNA4 Lung adenocarcinoma
35 20622 1 153317971 153326638 Amplification EFNA3 Lung adenocarcinoma
36 20838 1 154761820 154809020 Amplification IQGAP3 Lung adenocarcinoma
37 20853 1 154828181 154830715 Amplification APOA1BP Lung adenocarcinoma
38 20863 1 154936029 154941999 Amplification CRABP2 Lung adenocarcinoma
39 20868 1 154959036 154964835 Amplification ISG20L2 Lung adenocarcinoma
40 20872 1 154973717 154977547 Amplification MRPL24 Lung adenocarcinoma
41 20875 1 154978522 155003341 Amplification HDGF Lung adenocarcinoma
42 20983 1 155749790 155788934 Amplification FCRL5 Lung adenocarcinoma
43 21047 1 156490550 156494682 Amplification CD1A Lung adenocarcinoma
44 21335 1 158163454 158182010 Amplification IGSF9 Lung adenocarcinoma
45 21364 1 158264085 158268407 Amplification PIGM Lung adenocarcinoma
46 21422 1 158525000 158579978 Amplification COPA Lung adenocarcinoma
47 21516 1 159308119 159325966 Amplification PVRL4 Lung adenocarcinoma
48 21522 1 159336969 159354490 Amplification PFDN2 Lung adenocarcinoma
49 21527 1 159354514 159361857 Amplification NIT1 Lung adenocarcinoma
50 21533 1 159390157 159395270 Amplification UFC1 Lung adenocarcinoma

Expression for Lung Cancer Susceptibility 3

LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TNNC1 troponin C type 1 (slow) Lung - 5.28 0.000
2 COL11A1 collagen, type XI, alpha 1 Lung + 5.07 0.000
3 MMP1 matrix metallopeptidase 1 Lung + 4.75 0.000
4 AGER advanced glycosylation end product-specific receptor Lung - 4.69 0.000
5 WIF1 WNT inhibitory factor 1 Lung - 4.60 0.000
6 SOSTDC1 sclerostin domain containing 1 Lung - 4.47 0.000
7 FABP4 fatty acid binding protein 4, adipocyte Lung - 4.32 0.000
8 CDH3 cadherin 3, type 1, P-cadherin (placental) Lung + 4.31 0.000
9 FOSB FBJ murine osteosarcoma viral oncogene homolog B Lung - 4.24 0.000
10 TMEM100 transmembrane protein 100 Lung - 4.20 0.000
11 CLEC3B C-type lectin domain family 3, member B Lung - 4.18 0.000
12 FCN3 ficolin (collagen/fibrinogen domain containing) 3 Lung - 4.17 0.000
13 MT1M metallothionein 1M Lung - 4.07 0.000
14 SPP1 secreted phosphoprotein 1 Lung + 4.04 0.000
15 SPINK1 serine peptidase inhibitor, Kazal type 1 Lung + 3.96 0.000
16 COL10A1 collagen, type X, alpha 1 Lung + 3.79 0.000
17 CLIC5 chloride intracellular channel 5 Lung - 3.65 0.000
18 ADIRF adipogenesis regulatory factor Lung - 3.65 0.000
19 RAMP2 receptor (G protein-coupled) activity modifying protein 2 Lung - 3.62 0.000
20 HIGD1B HIG1 hypoxia inducible domain family, member 1B Lung - 3.60 0.000
21 STXBP6 syntaxin binding protein 6 (amisyn) Lung - 3.59 0.000
22 TMPRSS4 transmembrane protease, serine 4 Lung + 3.53 0.000
23 EFCC1 EF-hand and coiled-coil domain containing 1 Lung - 3.47 0.000
24 MFAP4 microfibrillar-associated protein 4 Lung - 3.47 0.000
25 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Lung + 3.47 0.000
26 TOP2A topoisomerase (DNA) II alpha Lung + 3.41 0.000
27 TCF21 transcription factor 21 Lung - 3.38 0.000
28 CA4 carbonic anhydrase IV Lung - 3.38 0.000
29 CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1 Lung - 3.33 0.000
30 GPM6A glycoprotein M6A Lung - 3.30 0.000
31 GINS2 GINS complex subunit 2 (Psf2 homolog) Lung + 3.29 0.000
32 NEK2 NIMA-related kinase 2 Lung + 3.27 0.000
33 TOX3 TOX high mobility group box family member 3 Lung + 3.24 0.000
34 IL1RL1 interleukin 1 receptor-like 1 Lung - 3.21 0.000
35 PKNOX2 PBX/knotted 1 homeobox 2 Lung - 3.21 0.000
36 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 Lung - 3.17 0.000
37 SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) Lung - 3.17 0.000
38 FIGF c-fos induced growth factor (vascular endothelial growth factor D) Lung - 3.14 0.000
39 CRABP2 cellular retinoic acid binding protein 2 Lung + 3.11 0.000
40 SGCG sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) Lung - 3.10 0.000
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 Lung - 3.08 0.000
42 SFTPD surfactant protein D Lung - 3.07 0.000
43 MARCO macrophage receptor with collagenous structure Lung - 3.07 0.000
44 COL1A1 collagen, type I, alpha 1 Lung + 3.05 0.000
45 NMU neuromedin U Lung + 3.05 0.000
Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.

Pathways for Lung Cancer Susceptibility 3

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.41 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
2
Show member pathways
14.26 AKT1 BRAF CTNNB1 EGFR ERBB2 FGFR3
3
Show member pathways
14.09 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
4
Show member pathways
14.06 AKT1 BRAF EGFR ERBB2 FGFR3 HRAS
5
Show member pathways
13.98 AKT1 BRAF CTNNB1 EGFR ERBB2 FGFR3
6
Show member pathways
13.97 AKT1 ALK BRAF CDK4 EGFR ERBB2
7
Show member pathways
13.95 AKT1 ALK BRAF EGFR ERBB2 FGFR3
8
Show member pathways
13.82 AKT1 ALK BRAF CTNNB1 EGFR ERBB2
9
Show member pathways
13.79 AKT1 ALK BRAF EGFR ERBB2 FGFR3
10
Show member pathways
13.77 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
11
Show member pathways
13.72 AKT1 EGFR ERBB2 FGFR3 HRAS KRAS
12
Show member pathways
13.68 AKT1 ALK EGFR ERBB2 FGFR3 HRAS
13
Show member pathways
13.65 AKT1 BRAF CTNNB1 EGFR HRAS KRAS
14
Show member pathways
13.65 AKT1 BRAF EGFR ERBB2 FGFR3 HRAS
15
Show member pathways
13.61 AKT1 ALK EGFR ERBB2 FGFR3 HRAS
16
Show member pathways
13.56 AKT1 ALK BRAF CTNNB1 EGFR ERBB2
17
Show member pathways
13.54 AKT1 CTNNB1 EGFR ERBB2 FGFR3 HRAS
18
Show member pathways
13.49 AKT1 BRAF EGFR ERBB2 HRAS KRAS
19
Show member pathways
13.47 AKT1 HRAS KRAS NRAS PIK3CA RAF1
20
Show member pathways
13.37 AKT1 BRAF EGFR FGFR3 HRAS KRAS
21
Show member pathways
13.36 AKT1 ALK EGFR FGFR3 HRAS KRAS
22
Show member pathways
13.32 AKT1 BRAF CTNNB1 EGFR HRAS KRAS
23
Show member pathways
13.3 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
24
Show member pathways
13.29 AKT1 EGFR HRAS KRAS MAP2K1 NRAS
25
Show member pathways
13.26 AKT1 CTNNB1 EGFR HRAS KRAS MAP2K1
26
Show member pathways
13.25 AKT1 CDK4 CTNNB1 EGFR HRAS KRAS
27 13.25 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
28
Show member pathways
13.25 AKT1 CDK4 CTNNB1 EGFR ERBB2 FGFR3
29
Show member pathways
13.23 AKT1 BRAF CDK4 CTNNB1 HRAS KRAS
30
Show member pathways
13.23 AKT1 BRAF EGFR HRAS KRAS MAP2K1
31
Show member pathways
13.21 ALK EGFR ERBB2 FGFR3 HRAS RAF1
32
Show member pathways
13.21 AKT1 BRAF EGFR ERBB2 HRAS KRAS
33
Show member pathways
13.2 AKT1 BRAF CTNNB1 EGFR ERBB2 HRAS
34
Show member pathways
13.17 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
35
Show member pathways
13.17 AKT1 BRAF EGFR ERBB2 FGFR3 HRAS
36
Show member pathways
13.17 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
37
Show member pathways
13.15 AKT1 HRAS KRAS MAP2K1 NRAS RAF1
38
Show member pathways
13.13 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
39
Show member pathways
13.12 BRAF HRAS KRAS MAP2K1 NRAS PIK3CA
40
Show member pathways
13.11 AKT1 HRAS KRAS MAP2K1 NRAS PIK3CA
41
Show member pathways
13.1 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
42 13.07 AKT1 BRAF EGFR ERBB2 FGFR3 HRAS
43
Show member pathways
13.05 AKT1 BRAF EGFR HRAS KRAS MAP2K1
44
Show member pathways
13.05 AKT1 EGFR ERBB2 FGFR3 HRAS KRAS
45
Show member pathways
13.04 AKT1 BRAF HRAS KRAS MAP2K1 PIK3CA
46
Show member pathways
13.03 AKT1 BRAF CTNNB1 EGFR FGFR3 HRAS
47
Show member pathways
13.02 AKT1 ALK BRAF CDK4 EGFR ERBB2
48
Show member pathways
13.01 AKT1 BRAF CTNNB1 ERBB2 HRAS KRAS
49
Show member pathways
13 AKT1 BRAF EGFR HRAS KRAS MAP2K1
50
Show member pathways
12.99 AKT1 CTNNB1 EGFR HRAS KRAS MAP2K1

GO Terms for Lung Cancer Susceptibility 3

Cellular components related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 focal adhesion GO:0005925 9.91 CTNNB1 EGFR FGFR3 KRAS MAP2K1
2 perinuclear region of cytoplasm GO:0048471 9.91 CDK4 CTNNB1 EGFR ERBB2 HRAS PRKN
3 plasma membrane GO:0005886 9.83 AKT1 ALK BRAF CTNNB1 EGFR ERBB2
4 protein-containing complex GO:0032991 9.8 AKT1 ALK CDK4 CTNNB1 EGFR PRKN
5 receptor complex GO:0043235 9.72 ALK EGFR ERBB2 FGFR3 ROS1
6 cytoplasm GO:0005737 9.55 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
7 intracellular GO:0005622 9.19 SMAD4
8 nucleus GO:0005634 10.33 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
9 membrane GO:0016020 10.33 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
10 mitochondrion GO:0005739 10.08 AKT1 BRAF KRAS MAP2K1 PRKN RAF1
11 Golgi apparatus GO:0005794 10.03 EGFR FGFR3 HRAS MAP2K1 NFE2L2 NRAS
12 cytosol GO:0005829 10 AKT1 BRAF CDK4 CTNNB1 ERBB2 KRAS

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.99 HRAS MAP2K1 STK11 TP53
2 T cell receptor signaling pathway GO:0050852 9.99 BRAF HRAS PIK3CA STK11
3 regulation of cell proliferation GO:0042127 9.99 ALK BRAF CDK4 CTNNB1 EGFR SMAD4
4 protein autophosphorylation GO:0046777 9.97 AKT1 ALK EGFR ERBB2 FGFR3 STK11
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.96 ALK EGFR ERBB2 ROS1
6 cell proliferation GO:0008283 9.96 AKT1 ALK CTNNB1 EGFR ERBB2 HRAS
7 Ras protein signal transduction GO:0007265 9.94 HRAS KRAS NRAS TP53
8 cellular response to drug GO:0035690 9.93 BRAF EGFR NFE2L2 TP53
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.93 HRAS KRAS NRAS RAF1
10 positive regulation of MAP kinase activity GO:0043406 9.92 EGFR ERBB2 HRAS KRAS
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.92 AKT1 BRAF EGFR PIK3CA RAF1
12 cellular response to growth factor stimulus GO:0071363 9.91 AKT1 CTNNB1 EGFR ERBB2
13 liver development GO:0001889 9.9 EGFR KRAS PIK3CA
14 positive regulation of cell growth GO:0030307 9.9 AKT1 EGFR ERBB2
15 regulation of signal transduction by p53 class mediator GO:1901796 9.9 AKT1 STK11 TP53
16 negative regulation of cell death GO:0060548 9.9 NFE2L2 PRKN SMAD4
17 positive regulation of epithelial cell proliferation GO:0050679 9.89 EGFR ERBB2 HRAS
18 negative regulation of neuron death GO:1901215 9.89 AKT1 CTNNB1 PRKN
19 epidermal growth factor receptor signaling pathway GO:0007173 9.88 AKT1 EGFR PIK3CA
20 somatic stem cell population maintenance GO:0035019 9.88 BRAF RAF1 SMAD4
21 positive regulation of MAPK cascade GO:0043410 9.88 CTNNB1 ERBB2 FGFR3 HRAS
22 negative regulation of apoptotic process GO:0043066 9.88 AKT1 BRAF CTNNB1 EGFR RAF1 TP53
23 cellular response to epidermal growth factor stimulus GO:0071364 9.87 AKT1 EGFR ERBB2
24 activation of MAPKK activity GO:0000186 9.87 BRAF EGFR RAF1
25 thymus development GO:0048538 9.87 BRAF CTNNB1 MAP2K1 RAF1
26 positive regulation of axonogenesis GO:0050772 9.86 BRAF MAP2K1 STK11
27 phosphatidylinositol 3-kinase signaling GO:0014065 9.85 AKT1 ERBB2 PIK3CA
28 ERBB2 signaling pathway GO:0038128 9.85 EGFR ERBB2 PIK3CA
29 regulation of cell motility GO:2000145 9.85 EGFR ERBB2 RAF1
30 positive regulation of protein phosphorylation GO:0001934 9.85 AKT1 EGFR ERBB2 HRAS KRAS RAF1
31 regulation of ERK1 and ERK2 cascade GO:0070372 9.84 EGFR ERBB2 ROS1
32 vasculature development GO:0001944 9.83 CTNNB1 PIK3CA STK11
33 thyroid gland development GO:0030878 9.83 BRAF MAP2K1 RAF1
34 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 BRAF EGFR FGFR3 HRAS MAP2K1
35 face development GO:0060324 9.82 BRAF MAP2K1